Hogar » Blockbuster Drug Model

Blockbuster Drug Model

1980
Pharmaceutical research laboratory focused on blockbuster drug development.

A “blockbuster drug” is a pharmaceutical product that generates more than $1 billion in annual sales for its manufacturer. This business model has historically driven the pharmaceutical industry, focusing research and development (R&D) on common, chronic conditions to maximize patent-protected revenue. This revenue funds further R&D for new drugs, creating a cycle of innovation and high profits.

The blockbuster model became the dominant strategy for large pharmaceutical companies in the late 20th century. The model relies on developing and patenting a drug that can treat a widespread chronic condition, such as high cholesterol (e.g., Lipitor), acid reflux (e.g., Prilosec), or depression (e.g., Prozac). Once approved, the company launches a massive marketing campaign aimed at both physicians and consumers (in countries where direct-to-consumer advertising is legal). The goal is to achieve widespread prescription and capture a large market share. The drug’s patentar provides a period of market exclusivity, typically 20 years from the filing date, during which the company can charge high prices without competition from generic versions. The enormous profits generated during this period are used to recoup the substantial R&D investment—often exceeding $1 billion per approved drug—and to fund the development of the next generation of potential blockbusters. However, this model faces significant challenges. The “low-hanging fruit” of common diseases has largely been addressed, making new discoveries more difficult. Increased pressure from payers (governments and insurance companies) to control costs, and the looming “patent cliff” (when patents for multiple blockbuster drugs expire around the same time), have forced the industry to reconsider this strategy. Many companies are now shifting towards developing more specialized, high-value drugs for smaller patient populations, such as orphan drugs for rare diseases or personalized cancer therapies, which can command even higher prices per patient.

UNESCO Nomenclature: 5312
– Economics of technological change

Tipo

Abstract System

Disruption

Incremental

Utilización

Widespread Use

Precursors

  • the bayh-dole act (1980) in the us, which encouraged commercialization of university research
  • el hatch-waxman act (1984), which established the modern system of patent extensions and generic drug approvals
  • advances in molecular biology that enabled rational drug design for common disease targets
  • growth of managed care and large-scale insurance payers

Aplicaciones

  • business strategy for major pharmaceutical companies (big pharma)
  • funding mechanism for large-scale r&d programs
  • marketing and sales strategies targeting large patient populations
  • justification for high drug prices during patent life

Patentes:

ESO

Potential Innovations Ideas

Membresía obligatoria de Professionals (100% free)

Debes ser miembro de Professionals (100% free) para acceder a este contenido.

Únete ahora

¿Ya eres miembro? Accede aquí
Related to: blockbuster drug, pharmaceutical economics, big pharma, patent cliff, drug prices, r&d, marketing, lipitor, propiedad intelectual, generic drugs.

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

DISPONIBLE PARA NUEVOS RETOS
Mechanical Engineer, Project, Process Engineering or R&D Manager
Desarrollo eficaz de productos

Disponible para un nuevo desafío a corto plazo.
Contáctame en LinkedIn
Plastic metal electronics integration, Design-to-cost, GMP, Ergonomics, Medium to high-volume devices & consumables, Lean Manufacturing, Regulated industries, CE & FDA, CAD, Solidworks, Lean Sigma Black Belt, medical ISO 13485

Estamos buscando un nuevo patrocinador

 

¿Su empresa o institución se dedica a la técnica, la ciencia o la investigación?
> Envíanos un mensaje <

Recibe todos los artículos nuevos
Gratuito, sin spam, correo electrónico no distribuido ni revendido.

o puedes obtener tu membresía completa -gratis- para acceder a todo el contenido restringido >aquí<

Historical Context

(if date is unknown or not relevant, e.g. "fluid mechanics", a rounded estimation of its notable emergence is provided)

Related Invention, Innovation & Technical Principles

Scroll al inicio

También te puede interesar